Tags

Type your tag names separated by a space and hit enter

The role of topical calcineurin inhibitors in atopic dermatitis.
Br J Dermatol 2004; 151 Suppl 70 Dec 2004:3-27BJ

Abstract

For more than five decades, topical corticosteroids and emollients have been the mainstay of therapy for atopic dermatitis. However, the potential for side-effects limits the clinical utility of corticosteroids in providing long-term disease control. With a unique mode of action that differs from that of corticosteroids, the steroid-free topical calcineurin inhibitors (TCIs), tacrolimus ointment and pimecrolimus cream, provide skin-selective treatment that targets key factors involved in the pathogenesis of this chronic disease. An extensive series of clinical trials involving more than 16,000 patients with predominantly moderate to severe atopic dermatitis in tacrolimus studies and over 2000 patients with primarily mild to moderate disease in pimecrolimus studies has shown that both TCIs provide effective and well-tolerated treatment for atopic dermatitis. Randomized controlled trials have demonstrated that tacrolimus is superior to conventional hydrocortisone-based regimens and does not cause skin atrophy or other steroidal side-effects. Both tacrolimus and pimecrolimus prevent disease flares and provide progressive and sustained disease improvement with long-term therapy. These and other clinical benefits of TCIs are discussed, together with the safety profiles of tacrolimus and pimecrolimus and their use in clinical practice. In addition, this review summarizes findings from the many trials carried out with these agents and outlines how TCIs can provide long-term treatment and control of a chronic skin disease that may persist for years.

Authors+Show Affiliations

Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Spain.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

15548171

Citation

Alomar, A, et al. "The Role of Topical Calcineurin Inhibitors in Atopic Dermatitis." The British Journal of Dermatology, vol. 151 Suppl 70 Dec 2004, 2004, pp. 3-27.
Alomar A, Berth-Jones J, Bos JD, et al. The role of topical calcineurin inhibitors in atopic dermatitis. Br J Dermatol. 2004;151 Suppl 70 Dec 2004:3-27.
Alomar, A., Berth-Jones, J., Bos, J. D., Giannetti, A., Reitamo, S., Ruzicka, T., ... Thestrup-Pedersen, K. (2004). The role of topical calcineurin inhibitors in atopic dermatitis. The British Journal of Dermatology, 151 Suppl 70 Dec 2004, pp. 3-27.
Alomar A, et al. The Role of Topical Calcineurin Inhibitors in Atopic Dermatitis. Br J Dermatol. 2004;151 Suppl 70 Dec 2004:3-27. PubMed PMID: 15548171.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The role of topical calcineurin inhibitors in atopic dermatitis. AU - Alomar,A, AU - Berth-Jones,J, AU - Bos,J D, AU - Giannetti,A, AU - Reitamo,S, AU - Ruzicka,T, AU - Stalder,J-F, AU - Thestrup-Pedersen,K, AU - ,, PY - 2004/11/19/pubmed PY - 2005/3/24/medline PY - 2004/11/19/entrez SP - 3 EP - 27 JF - The British journal of dermatology JO - Br. J. Dermatol. VL - 151 Suppl 70 Dec 2004 N2 - For more than five decades, topical corticosteroids and emollients have been the mainstay of therapy for atopic dermatitis. However, the potential for side-effects limits the clinical utility of corticosteroids in providing long-term disease control. With a unique mode of action that differs from that of corticosteroids, the steroid-free topical calcineurin inhibitors (TCIs), tacrolimus ointment and pimecrolimus cream, provide skin-selective treatment that targets key factors involved in the pathogenesis of this chronic disease. An extensive series of clinical trials involving more than 16,000 patients with predominantly moderate to severe atopic dermatitis in tacrolimus studies and over 2000 patients with primarily mild to moderate disease in pimecrolimus studies has shown that both TCIs provide effective and well-tolerated treatment for atopic dermatitis. Randomized controlled trials have demonstrated that tacrolimus is superior to conventional hydrocortisone-based regimens and does not cause skin atrophy or other steroidal side-effects. Both tacrolimus and pimecrolimus prevent disease flares and provide progressive and sustained disease improvement with long-term therapy. These and other clinical benefits of TCIs are discussed, together with the safety profiles of tacrolimus and pimecrolimus and their use in clinical practice. In addition, this review summarizes findings from the many trials carried out with these agents and outlines how TCIs can provide long-term treatment and control of a chronic skin disease that may persist for years. SN - 0007-0963 UR - https://www.unboundmedicine.com/medline/citation/15548171/The_role_of_topical_calcineurin_inhibitors_in_atopic_dermatitis_ L2 - https://onlinelibrary.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=0007-0963&date=2004&volume=151&issue=&spage=3 DB - PRIME DP - Unbound Medicine ER -